Biocytogen and Whitehawk partner to develop ADCs

Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership. The collaboration leverages Biocytogen’s antibody capabilities and Whitehawk’s ADC expertise to identify BsADCs. Whitehawk Therapeutics will assess the antibodies in conjunction with its ADC linker-payload platform. Credit: Gorodenkoff / Shutterstock.com. Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership. Under this collaboration, Biocytogen will offer access to up to five bispecific antibodies via its RenLite platform. NPVM: ADC Therapeutics SA's ADCT-602 Reports NPVM: ADC Therapeutics SA's Camidanlumab tesirine Go deeper with GlobalData The…

Source: Pharmaceutical Technology